Genetics and gene therapy
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.
Search
Search results
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Meet our Ambassador: Bhavini Makwana
Her work with us enables her to achieve her aim of empowering others living with similar conditions to her own.
New stem cell treatment gains approval to enter US clinical trials
New stem cell treatment gains approval to enter US clinical trials
jCyte update
In spring 2021, the US company jCyte announced detailed results from their successful phase 2b clinical trial of jCell, a stem cell-based treatment for RP.
A fond farewell and a warm welcome
After more than 10 years of service as Chair of the Board of Trustees, Don Grocott has retired.
Optogenetics
The BBC covered a story on Monday 24 May about optogenetics partially restoring the sight of a man living with retinitis pigmentosa in France.
Amar Latif ‘delighted’ to be an ambassador for Retina UK
We are proud to announce that Amar Latif - adventurer, entrepreneur, TV presenter and public speaker - is to join Retina UK as a volunteer ambassador.
e-Newsletter February 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.